Epithelial ovarian cancer: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
| Line 21: | Line 21: | ||
* Inhibition of apoptosis | * Inhibition of apoptosis | ||
|- | |- | ||
|Human Epidermal Growth Factor Receptor 2 (HER-2) | |Human Epidermal Growth Factor Receptor 2 (HER-2)<ref name="pmid28513565">{{cite journal |vauthors=Wee P, Wang Z |title=Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways |journal=Cancers (Basel) |volume=9 |issue=5 |pages= |date=May 2017 |pmid=28513565 |pmc=5447962 |doi=10.3390/cancers9050052 |url=}}</ref><ref name="pmid25276427">{{cite journal |vauthors=Iqbal N, Iqbal N |title=Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications |journal=Mol Biol Int |volume=2014 |issue= |pages=852748 |date=2014 |pmid=25276427 |pmc=4170925 |doi=10.1155/2014/852748 |url=}}</ref> | ||
| | | | ||
* Promotes cell prolifeartion | * Promotes cell prolifeartion | ||
Revision as of 15:18, 26 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]
| Possible genetic alteration in epithelial ovarian cancers | ||
|---|---|---|
| Protein | Normal function | Result of mutation |
| Epidermal growth factor receptor (HER-1)[1][2] |
|
|
| Human Epidermal Growth Factor Receptor 2 (HER-2)[1][2] |
|
|
| Src | ||
| CSF-1/fms | ||
| ILGF/ILGFR | ||
| k-ras | ||
| b-raf | ||
| TGF-β | ||
| myc | ||
| Cyclin D/Cdk4/6 | ||
| Cyclin E/Cdk2 | ||
| Cyclin B/Cdk1 | ||
| p16 | ||
| p27 (kip-1) | ||
| p21 (WAF-1) | ||
| NFκB | ||
| NOEY(ARHI) | ||
| PIP3/Akt | ||
| PTEN | ||
| p53 | ||
| BRCA1 | ||
| BRCA2 | ||
| MLH1/MSH2 | ||
| Fas ligand | ||
| HLA-G | ||
| hTERT | ||
| VEGF/VEGFR | ||
| IL-8 | ||
| EphA2 | ||
| MMPs | ||
| αvβ3 | ||
| FAK | ||
| E-cadherin | ||
References
- ↑ 1.0 1.1 Wee P, Wang Z (May 2017). "Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways". Cancers (Basel). 9 (5). doi:10.3390/cancers9050052. PMC 5447962. PMID 28513565.
- ↑ 2.0 2.1 Iqbal N, Iqbal N (2014). "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications". Mol Biol Int. 2014: 852748. doi:10.1155/2014/852748. PMC 4170925. PMID 25276427.